Turn Therapeutics TTRX 深 沪
等待开盘 10-21 09:30:00 美东时间
10.605
-0.135
-1.26%
华盛通- 最 高10.74
- 今 开10.54
- 成交量 1.96万股
- 最 低 10.38
- 昨 收 10.74
- 总市值 3.22亿
- 52周最高 16.45
- 市盈率 静 --
- 换手率 0.06%
- 52周最低 2.5701
- 委 比 99.06%
- 总股本 3036.77万
- 历史最高 26.50
- 量 比 0.39
- 振 幅 3.35%
- 历史最低 2.5701
- 每 手 1
- 风险率 3.30%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Turn Therapeutics Inc收跌8.8%，成交额113.29万美元
10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势，更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
10-17 06:27
Short Interest Alert: Most and least shorted sub-$2B healthcare stocks in Sep. 2026
Short interest data from late September 2026 highlights deeply divided investor sentiment across small-cap healthcare stocks (market capitalizations up to $2B). Heavy bearish bets remain concentrated ...
10-02 22:15
美股大行评级 | Meta获4家机构齐升目标价，最高看至995美元！麦当劳遭6家机构下调，最低看至260美元
今日重点评级关注：Canaccord Genuity：维持Aurora Innovation"买入"评级，目标价从15美元升至17美元；摩根大通：维持皇家加勒比邮轮"超配"评级，目标价从345美元升至394美元
09-25 15:55
LUCID CAPITAL MARKETS Initiates Coverage On Turn Therapeutics with Buy Rating, Announces Price Target of $24
LUCID CAPITAL MARKETS analyst Dev Prasad initiates coverage on Turn Therapeutics (NASDAQ:TTRX) with a Buy rating and announces Price Target of $24.
09-24 19:38
美股大行评级 | 机构看淡消费股！麦当劳、耐克、卡夫亨氏齐遭降目标价；能源股获齐声唱多
今日重点评级关注：Ascendiant Capital：维持SurgePays"买入"评级，目标价从3.5美元升至3.75美元；HC Wainwright & Co.：维持Spero Therapeutics"买入"评级，目标价从5美元升至6美元
09-15 15:30
WBB Securities Downgrades Turn Therapeutics to Sell, Announces $10 Price Target
WBB Securities analyst Karen Sterling downgrades Turn Therapeutics (NASDAQ:TTRX) from Hold to Sell and announces $10 price target.
09-15 00:11
Turn Therapeutics to Present Atopic Dermatitis Strategy
Turn Therapeutics Inc ( ($TTRX) ) has issued an announcement. On September 10, ...
09-10 20:29
Turn Therapeutics Names Robert Redfield Chief Scientific Officer
Turn Therapeutics Inc ( ($TTRX) ) just unveiled an announcement. On September 9...
09-09 20:36
Turn Therapeutics To Present Data On Its Interim Analysis Of Its Current Adaptive Phase 2 Study Of GX-03 In Atopic Dermatitis
Turn Therapeutics, Inc. (NASDAQ:TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory skin diseases, today announced it will host a live webcast on Tuesday, July 7, 2026, to present key findings from the comprehensive interim analysis of its ongoi...
07-07 04:02
Turn Therapeutics Announces Interim Analysis Findings From First 50 Completed Subjects Enrolled In Ongoing Randomized, Double-Blind, Vehicle-Controlled Phase 2 Clinical Trial Evaluating GX-03 In Adults With Atopic Dermatitis
92.6% of GX-03-treated subjects achieved a 50% reduction in eczema severity in 4 weeks (EASI-50); 70.4% achieved a 75% reduction in 4 weeks (EASI-75); 44.4% achieved a 90% reduction in 4 weeks (EASI-90); and 51.9%
06-01 20:36
